Kate Goodwin

After the FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder, companies are pivoting away from or delaying similar therapeutics targeting the psychiatric disease.

London Design Festival (LDF) has just finished and, with a number of programmes and exhibitions still running, Kate Goodwin reports on the highlights across the city.

On the heels of Keytruda's success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.

After four patient deaths, Kezar's lupus trial is officially on hold, sparking investor Kevin Tang's interest for acquisition.

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.

With Eisai and Biogen's Leqembi and Eli Lilly's Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer's Disease conference focused on the role these drugs might play, as well as combination therapies and innovative new treatment options.

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a continued appetite for these drugs.

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it's evaluating its options for the program.

Investigational CAR T therapies stole the spotlight at the American College of Rheumatology Convergence as data presented by Bristol Myers Squibb, Kyverna Therapeutics and more highlighted their potential to effectively treat lupus.